Ekso Bionics Holdings Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $18.40 million
- Book Value:
- Revenue TTM:
- $13.44 million
- Operating Margin TTM:
- Gross Profit TTM:
- $6.75 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Ekso Bionics Holdings Inc had its IPO on 2014-01-16 under the ticker symbol EKSO.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Ekso Bionics Holdings Inc has a staff strength of 55 employees.
Shares of Ekso Bionics Holdings Inc opened at $1.4 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $1.34 - $1.46, and closed at $1.35.
This is a -3.57% slip from the previous day's closing price.
A total volume of 62,200 shares were traded at the close of the day’s session.
In the last one week, shares of Ekso Bionics Holdings Inc have slipped by -6.9%.
Ekso Bionics Holdings Inc's Key Ratios
Ekso Bionics Holdings Inc has a market cap of $18.40 million, indicating a price to book ratio of 0.6798 and a price to sales ratio of 1.3595.
In the last 12-months Ekso Bionics Holdings Inc’s revenue was $13.44 million with a gross profit of $6.75 million and an EBITDA of $-15261000. The EBITDA ratio measures Ekso Bionics Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ekso Bionics Holdings Inc’s operating margin was -116.63% while its return on assets stood at -21.76% with a return of equity of -43.63%.
In Q3, Ekso Bionics Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 9.2%.
Ekso Bionics Holdings Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ekso Bionics Holdings Inc’s profitability.
Ekso Bionics Holdings Inc stock is trading at a EV to sales ratio of 0.0456 and a EV to EBITDA ratio of 0.4444. Its price to sales ratio in the trailing 12-months stood at 1.3595.
Ekso Bionics Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $39.31 million
- Total Liabilities
- $7.86 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Ekso Bionics Holdings Inc ended 2023 with $39.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $39.31 million while shareholder equity stood at $28.61 million.
Ekso Bionics Holdings Inc ended 2023 with $0 in deferred long-term liabilities, $7.86 million in other current liabilities, 13000.00 in common stock, $-220769000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29.18 million and cash and short-term investments were $29.18 million. The company’s total short-term debt was $2,240,000 while long-term debt stood at $0.
Ekso Bionics Holdings Inc’s total current assets stands at $36.75 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $3.40 million compared to accounts payable of $2.39 million and inventory worth $3.51 million.
In 2023, Ekso Bionics Holdings Inc's operating cash flow was $-141000.00 while its capital expenditure stood at $141000.
Comparatively, Ekso Bionics Holdings Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Ekso Bionics Holdings Inc stock is currently trading at $1.35 per share. It touched a 52-week high of $3.15 and a 52-week low of $3.15. Analysts tracking the stock have a 12-month average target price of $9.
Its 50-day moving average was $1.6 and 200-day moving average was $1.67 The short ratio stood at 1.91 indicating a short percent outstanding of 0%.
Around 833% of the company’s stock are held by insiders while 1467.3% are held by institutions.
Frequently Asked Questions About Ekso Bionics Holdings Inc
Similar Industry Stocks (Medical Instruments & Supplies)
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer’s shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.